CD22 and precursor B-cell acute lymphoblastic leukemia: Instead, we noted instances of antigen+ relapses, which have also been reported in clinical trials of CD19/CD22 CAR-T cells for B-ALL and LBCL [8, 15, 19, 29], as well as CD19/CD20 CAR-T cells for LBCL [33].